This page brings together the European Medicines Agency's (EMA) latest information on cancer. It lists:
Ibrance is a cancer medicine used to treat breast cancer when the cancer is locally advanced (has spread nearby) or metastatic (has spread to other parts of the body). Ibrance can only be used when...
Empliciti is a medicine for treating multiple myeloma (a cancer of the bone marrow). It is used together with two other medicines (lenalidomide and dexamethasone) and is given to adults who have...
This is a summary of the European public assessment report (EPAR) for Armisarte. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use...
This is a summary of the European public assessment report (EPAR) for Potactasol. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion...
MabThera is a medicine used to treat the following blood cancers and inflammatory conditions: follicular lymphoma and diffuse large B cell non-Hodgkin’s lymphoma (two types of non-Hodgkin’s lymphoma...
Nine new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended nine medicines for approval at its March 2023 meeting. The CHMP recommended authorising the COVID-19 vaccine Bimervax (previously COVID-19 Vaccine HIPRA)...
Eight new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended granting a marketing authorisation for Akeega (niraparib/abiraterone acetate) for the treatment of metastatic castration-resistant prostate cancer with...
Five new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended five medicines for approval at its December 2022 meeting. The CHMP recommended granting a conditional marketing authorisation for the advanced therapy...
EMA has recommended a conditional marketing authorisation in the European Union (EU) for Tecvayli (teclistamab) for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies,...
EMA’s human medicines committee, CHMP, has recommended that Rubraca (rucaparib camsylate) should no longer be used as third-line treatment for cancers of the ovary, fallopian tubes or peritoneum with a BRCA mutation in patients whose cancer has come...
Nine new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended nine medicines for approval at its June 2022 meeting. The CHMP recommended granting a marketing authorisation for COVID-19 Vaccine (inactivated,...
The third Cancer Medicines Forum took place on the 20th December 2022 and looked at challenges...
The EMA's Cancer Medicines Forum (CMF) aims to explore how EMA can contribute towards addressing...
This first meeting of EMA's Cancer Medicines Forum looked at challenges around research into...
The European Medicines Agency is hosting a symposium to explore themes such as the natural...